Stock KAN KANCERA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kancera AB

Equities

KAN

SE0015658570

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:47 2024-04-26 am EDT 		5-day change 1st Jan Change
1.412 SEK -2.49% Intraday chart for Kancera AB -4.98% -68.93%
Feb. 23 Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 23 Kancera AB Signs A License Agreement with the University of Newcastle CI

Valuation

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Capitalization 1 166.9 96.52 344.2 168.9 171.1 171.1 -
Enterprise Value (EV) 1 146.5 85.25 344.2 73.78 370.4 171.1 171.1
P/E ratio - - -7.48 x -2.37 x -9.28 x -2.02 x 3.53 x
Yield - - - - - - -
Capitalization / Revenue 466 x 30 x - 224 x 358 x - 2.48 x
EV / Revenue 466 x 30 x - 224 x 358 x - 2.48 x
EV / EBITDA - - - -3.28 x -5.97 x -2.1 x 3.18 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 19,054 20,983 56,144 79,308 121,186 121,186 -
Reference price 2 8.760 4.600 6.130 2.130 1.412 1.412 1.412
Announcement Date 2/22/19 2/21/20 2/18/22 2/21/23 2/23/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Net sales 1 0.358 3.216 - 0.753 1.035 - 68.9
EBITDA 1 - - - -51.57 -62.04 -81.3 53.8
EBIT 1 -45.92 -35.65 - -51.93 -65.04 -81.3 53.8
Operating Margin -12,827.09% -1,108.61% - -6,896.95% -6,284.25% - 78.08%
Earnings before Tax (EBT) 1 - - - -52.48 -64.89 -81.3 53.8
Net income 1 - - -45.69 -52.48 -64.89 -81.3 53.8
Net margin - - - -6,969.99% -6,269.47% - 78.08%
EPS 2 - - -0.8200 -0.9000 -0.4900 -0.7000 0.4000
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 2/22/19 2/21/20 2/18/22 2/21/23 2/23/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 - - - 0.443 - - -
EBITDA 1 -17.1 -18.23 -10.48 -18.99 -20.3 -20.3 -20.3
EBIT 1 -17.19 -18.32 -10.55 -18.99 -20.3 -20.3 -20.3
Operating Margin - - - -4,285.78% - - -
Earnings before Tax (EBT) 1 -17.5 -18.19 -10.73 -18.47 -20.3 -20.3 -20.3
Net income - - - - - - -
Net margin - - - - - - -
EPS 2 -0.2200 -0.2300 -0.1300 -0.2300 -0.2000 -0.1700 -0.1700
Dividend per Share - - - - - - -
Announcement Date 5/19/23 8/18/23 11/17/23 2/23/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 20.4 11.3 - 95.1 - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 2/22/19 2/21/20 2/18/22 2/21/23 2/23/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Kancera AB

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
KANCERA AB Stock Kancera AB
-68.93% 15.61M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. KAN Stock
  4. Financials Kancera AB